Loading…
Newborn Screening Saves Lives Reauthorization Act of 2019
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
89pct
84d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Newborn Screening Saves Lives Reauthorization Act of 2019 This bill reauthorizes through FY2024 and revises several programs and activities relating to newborn screening for genetic diseases. Among other things, the bill reauthorizes, and makes mandatory rather than discretionary, the Hunter Kelly Research Program at the National Institutes of Health as well as national surveillance activities conducted by the Centers for Disease Control and Prevention.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (22)
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7365-7367)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H7365-7367)
DEBATE - The House proceeded with forty minutes of debate on H.R. 2507.
Considered under suspension of the rules. (consideration: CR H7365-7368)
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 134.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-174.
Congress.gov source codes: 5000, H12200
Ordered to be Reported (Amended) by Voice Vote.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2023 · first_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Client expense: $780,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Client expense: $700,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Client expense: $790,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Client expense: $790,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Client expense: $900,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Committee Consideration and Mark-up Session Held.
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Subcommittee Consideration and Mark-up Session Held.
Subcommittee Hearings Held.
Sponsor introductory remarks on measure. (CR H3796)
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| House |
| Referred to |
| May 2, 2019 |
| May 2, 2019 |
| Republican |
| KY |
| Brian Higgins | Democratic | NY |
| Brian K. Fitzpatrick | Republican | PA |
| Cathy McMorris Rodgers | Republican | WA |
| Charles J. "Chuck" Fleischmann | Republican | TN |
| Chris Collins | Republican | NY |
| Chris Pappas | Democratic | NH |
| Chris Stewart | Republican | UT |
| Cynthia Axne | Democratic | IA |
| Darren Soto | Democratic | FL |
| David Scott | Democratic | GA |
| Debbie Dingell | Democratic | MI |
| Diana DeGette | Democratic | CO |
| Donna E. Shalala | Democratic | FL |
| Doug Lamborn | Republican | CO |
| Ed Case | Democratic | HI |
| Eleanor Holmes Norton | Democratic | DC |
| Harley Rouda | Democratic | CA |
| Jaime Herrera Beutler | Republican | WA |
| James A. Himes | Democratic | CT |
| Jamie Raskin | Democratic | MD |
| Jim Hagedorn | Republican | MN |
| Joe Neguse | Democratic | CO |
| John A. Yarmuth | Democratic | KY |
| John R. Carter | Republican | TX |
| Joseph P. Kennedy III | Democratic | MA |
| Katherine M. Clark | Democratic | MA |
| Kathleen M. Rice | Democratic | NY |
| Kathy Castor | Democratic | FL |
| Ken Calvert | Republican | CA |
| Lisa Blunt Rochester | Democratic | DE |
| Marcia L. Fudge | Democratic | OH |
| Mary Gay Scanlon | Democratic | PA |
| Michael K. Simpson | Republican | ID |
| Peter Welch | Democratic | VT |
| Raúl M. Grijalva | Democratic | AZ |
| Robin L. Kelly | Democratic | IL |
| Ruben Gallego | Democratic | AZ |
| Sean Casten | Democratic | IL |
| Steve Cohen | Democratic | TN |
| Steve Stivers | Republican | OH |
| Steve Watkins | Republican | KS |
| Susan A. Davis | Democratic | CA |
| Susan W. Brooks | Republican | IN |
| Ted Lieu | Democratic | CA |
| Tom Cole | Republican | OK |
| Yvette D. Clarke | Democratic | NY |
2022 · first_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Client expense: $900,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 4439/S.4010, Creating Hope Reauthorization Act; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Client expense: $730,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 4439/S.4010, Creating Hope Reauthorization Act; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Client expense: $730,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 4439/S.4010, Creating Hope Reauthorization Act; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act.
Client expense: $720,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Telehealth; H.R. 4439/S. 4010, Creating Hope Reauthorization Act; H.R. 2507 / S. 2158, Newborn Screening Saves Lives Reauthorization Act; and S. 2061, Telemental Healthcare Access Act of 2021.
Client expense: $700,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Health Issues
Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives; drug pricing proposals; access to rare disease and gene therapy drugs; and FDA approvals of drugs designed to treat rare diseases, including gene therapies. Issues pertaining to newborn screening and gene panel screening, including, H.R. 2507, the Newborn Screening Saves Lives Reauthorization Act of 2019 and S. 2158, the Newborn Screening Saves Lives Reauthorization Act of 2019 (116th Congress). Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA) and the orphan drug tax credit; Issues related to the use of plasma therapies in COVID-19 patients; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; The Patient Affordability, Value and Efficiency Act (not yet introduced); Discussions related to co-pay accumulators; H.R. 2279, S. 2546, Safe Step Act - provisions related to step therapy policy; H.R. 3276, S. 1785, Fair AMP Act - provisions related to AMP cap, exclusion of authorized generics from AMP; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; H.R. 2507, S. 2158, Newborn Screening Saves Lives Reauthorization of 2019 - provisions related to newborn screening; H.R. 6800, The Heroes Act - provisions related to tax issues and plasma treatments; Discussions related to Most Favored Nation/International Reference Pricing including the Executive Order; E.O. 13937, Access to Affordable Life-Saving Medications; E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients; E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen; E.O. 13947, 13948, Lowering Drug Prices by Putting America First; E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States; E.O. 13951, An America-First Healthcare Plan; E.O 13950, Combating Race and Sex Stereotyping.
Client expense: $420,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA) and the orphan drug tax credit; Issues related to the use of plasma therapies in COVID-19 patients; Communications with DFC regarding Project Warp Speed - provisions related to use of plasma to treat COVID-19; H.R. 1425, The Patient Protection and Affordable Care Enhancement Act Discussions to clarify or reform the 340B program; S.4160 - A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes - provisions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; H.R. 1035; Prescription Drug Price Transparency Act - provisions related to drug pricing transparency and pharmacy benefit managers; S. 378, H.R. 1093, The Stop Price Gouging Act - provisions related to prescription drug pricing; Discussions related to co-pay accumulators; S. 657, Drug Price Transparency Act - provisions related to prescription drug pricing transparency and commercial market rebates; H.R. 2279, S. 2546, Safe Step Act - provisions related to step therapy policy; H.R. 3276, S. 1785, Fair AMP Act - provisions related to AMP cap, exclusion of authorized generics from AMP; H.R. 3, Lower Drug Costs Now Act of 2019 - provisions related to the establishment of programs and requirements relating to the prices of prescription drugs; H.R. 19, Lower Costs, More Cures Act of 2019 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; VA MISSION Act of 2018 (P.L. 115 - 182) - provisions related to healthcare coverage after dischange from active duty; H.R. 5201, Telemental Health Expansion Act of 2019 - provisions related to mental telehealth coverage; Issues related to global pharmaceutical supply chain operations and manufacturing locations; H.R. 2507, S. 2158, Newborn Screening Saves Lives Reauthorization of 2019 - provisions related to newborn screening; H.R. 6800, The Heroes Act - provisions related to tax issues and plasma treatments; Discussions related to Most Favored Nation/International Reference Pricing including the Executive Order; E.O. 13937, Access to Affordable Life-Saving Medications; E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients; E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen; E.O. 13947, 13948, Lowering Drug Prices by Putting America First; E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States; E.O. 13951, An America-First Healthcare Plan; E.O 13950, Combating Race and Sex Stereotyping.
Client expense: $1,190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2020 · fourth_quarter · Health Issues
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for passage of H.R. 4393, the Advancing Access to Precision Medicine Act, provide for a State option under the State Medicaid plan to provide DNA sequencing clinical services for certain children. Advocated for funding for the FDA Orphan Products Grants Program. Advocated for passage of H.R. 3235, the Access to Genetic Counselor Services Act of 2019, to provide for expanded coverage of services provided by genetic counselors. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 2507 / S. 2158, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for robust funding of the national newborn screening program. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019. Advocated for maintaining strong incentives for rare disease drug development included within the Orphan Drug Act (PL 97-414) Advocated on the Promising Pathway Act (S.3872) and the ACT for ALS Act (H.R.7071). Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency. H.R. 6800, HEROES Act and related COVID-19 packages, support various provisions relevant to people with NMDs including increased federal support for state Medicaid programs; Medicaid maintenance of effort provisions; nationwide reopening of Marketplace special enrollment period; expansion of paid sick leave and paid family and medical leave; making permanent flexibilities to allow Medicare beneficiaries to continue accessing healthcare through telehealth; more resources to enhance testing and contact tracing in underserved communities; opposing waivers from IDEA and the Rehab Act; and better data collection on the impact of COVID-19 on people with disabilities. Continuing to support passage of legislation and proposals to protect patients from surprise medical billing and hold patients harmless.
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2020 · fourth_quarter · Health Issues
Legislation and policies relating to: Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Reauthorization of funding for the Childrens Health Insurance Program Reauthorization of the Child Nutrition Act Section 2706 of the ACA regarding provider non-discrimination Policies related to health insurance market stabilization Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Health information technology and electronic health records Mental health services and violence prevention Human and child trafficking Palliative Care and Hospice Education and Training Act (H.R. 647/S. 2080) Title VIII Nursing Workforce Reauthorization Act of 2019 (H.R. 728/S. 1399) Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748/S.3548) Emergency Medical Services for Children Program Reauthorization Act of 2019 (H.R. 776/S. 1173) End Surprise Billing Act of 2019 (H.R. 861) Fairness for Breastfeeding Mothers Act (H.R. 866/S. 528) Heroes Act (H.R. 925) Mental Health Access Improvement Act of 2019 (H.R. 945) Mental Health Services for Students Act of 2019 (H.R. 1109) Workplace Violence Prevention for Health Care and Social Service Workers Act (H.R. 1309) Competitive Health Insurance Reform Act of 2020 (H.R. 1418) Patient Protection and Affordable Care Enhancement Act (H.R. 1425) Healthy Families Act (H.R. 1784/S. 840) Mothers and Offspring Mortality and Morbidity Awareness (MOMMAs) Act (H.R. 1897) School-Based Health Centers Reauthorization Act of 2019 (H.R. 2075/S. 1013) Scarlett's Sunshine on Sudden Unexpected Death Act (H.R. 2271/S. 1130) Easy MAT for Opioid Addiction Act (H.R. 2281) Community Health Investment, Modernization, and Excellence Act of 2019 (H.R. 2328) Newborn Screening Saves Lives Reauthorization Act of 2019 (H.R. 2507) Pregnant Workers Fairness Act (H.R. 2694) Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act of 2019 (H.R. 2781) Vaccine Awareness Campaign to Champion Immunization Nationally and Enhance Safety (VACCINES) Act of 2019 (H.R. 2862) Physical Activities Recommendations for Americans Act of 2019 (H.R. 2891) Safe Cribs Act of 2019 (H.R. 3170) Safe Sleep for Babies Act of 2019 (H.R. 3172) Pathways to Health Careers Act (H.R. 3398) Chronic Care Management Improvement Act (H.R. 3436) No Surprises Act (H.R. 3630) Midwives for Maximizing Optimal Maternity Services (Midwives for MOMS) Act of 2019 (H.R. 3849) Social Determinants Accelerator Act of 2019 (H.R. 4004/S. 2986) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 (H.R. 3328/H.R. 4100/S. 1712) Effective Suicide Screening and Assessment in the Emergency Department Act of 2019 (H.R. 4861/S. 3006) United States Public Health Service Modernization Act of 2019 (H.R. 4870/S. 2629) Medication Access and Training Expansion (MATE) Act of 2019 (H.R. 4974) Maternal Health Quality Improvement Act of 2019 (H.R. 4995) Helping Medicaid Offer Maternity Services (MOMS) Act of 2019 (H.R. 4996) Protecting Seniors Through Immunization Act of 2019 (H.R. 5076/S. 1872) Pursuing Equity in Mental Health Act of 2019 (H.R. 5469) Primary and Behavioral Health Care Access Act (H.R. 5575) Ban Surprise Billing Act (H.R. 5800) Consumer Protections Against Surprise Medical Bills Act of 2020 (H.R. 5826) Black Maternal Health Momnibus Act of 2020 (H.R. 6142/S. 3424) Families First Coronavirus Response Act (H.R. 6201) Take Responsibility for Workers and Families Act (H.R. 6379) Health Care at Home Act (H.R. 6644) COVID-19 Mental Health Research Act (H.R. 6645) HEROES Act (H.R. 6800) Child Care Is Essential Act (H.R. 7027) Ensuring Children and Child Care Workers Are Safe Act of 2020 (H.R. 7079) Child Care for Economic Recovery Act (H.R. 7327) Protect Telehealth Access Act (H.R. 7391) Protecting Access to Post-COVID-19 Telehealth Act of 2020 (H.R. 7663) Community and Public Health Programs Extension Act (S. 192) National Nurse Act of 2019 (S. 696/H.R. 1597) Excellence in Mental Health and Addiction Treatment Expansion Act (S. 824/H.R. 1767) Nursing Where It's Needed Act (S. 1045) Promoting Physical Activity for Americans Act (S. 1608) Lower Health Care Costs Act (S. 1895) National Suicide Hotline Designation Act (S. 2661) Child Care Protection Improvement Act of 2019 (S. 2683) CONNECT for Health Act of 2019(S. 2741/H.R. 4932) CAPTA Reauthorization Act of 2019 (S. 2971) Suicide Prevention Act (S. 3198/H.R. 5619) Eliminating Abusive and Rampant Neglect of Interactive Technologies (EARN IT) Act of 2020 (S. 3398) Tele-Mental Health Improvement Act (S. 3792) Coronavirus Mental Health and Addiction Assistance Act of 2020 (S. 3825/H.R. 6999) Mental and Behavioral Health Connectivity Act (S. 3999) Future Advancement of Academic Nursing (FAAN) Act (S. 4396/H.R. 7945) Safe Authorization for Vaccines during Emergencies (SAVE) Act (S. 4427) Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act of 2020 (S. 4760)
Client expense: Not reported · Firm income: $24,000
Government targets: Bureau of Alcohol Tobacco Firearms & Explosives, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, Veterans Affairs, Dept of (VA), Vice President of the U.S., White House Office
2020 · fourth_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients; H.R. 133, Consolidated Appropriations Act of 2021.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
H.R. 133: Consolidated Appropriations Act, 2021; Discussions surrounding additional coronavirus relief measures; provisions related to paid family and medical leave, personal protective equipment, and access to medicine, nutrition assistance programs, and antimicrobial research H.R. 2507: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions H.R. 4100: Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019; all provisions H.R. 4386: Stop the Wait Act; all provisions H.R. 4932: Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019; all provisions H.R. 6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; provisions related to paid family and medical leave, personal protective equipment, and access to medicine, nutrition assistance programs, and antimicrobial research H.R. 8920: The Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020; all provisions S. 1712: Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019; all provisions S. 2158: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions S. 2496: Stop the Wait Act; all provisions S. 2741: Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019; all provisions S. 4421: Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act; all provisions S. 4557: COVID Enrollment Response (COVER) Act; all provisions S. 4760: The Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020; all provisions
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
H.J. Res. 110: Extension of Continuing Appropriations Act, 2021; provisions related to funding for Health and Human Services and related agencies, Food and Drug Administration and related agencies, funding for nutrition assistance programs, and medical expense deduction H.R. 133: Consolidated Appropriations Act, 2021; Discussions surrounding additional coronavirus relief measures; provisions related to paid family and medical leave, personal protective equipment, and access to medicine, nutrition assistance programs, and antimicrobial research, funding for Department of Health and Human Services (HHS) and related agencies, Food and Drug Administration (FDA) and related agencies H.R. 2507: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions H.R. 4932: Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019; all provisions H.R. 6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; Provisions related to paid family and medical leave, personal protective equipment, and access to medicine, nutrition assistance programs, and antimicrobial research H.R. 8920: The Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020; all provisions S. 2158: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions S. 2741: Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019; all provisions S. 4760: The Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020; all provisions
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
S. 2158 / H.R. 2507--Newborn Screening Saves Lives Reauthorization Act Executive Order 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States General issues related to orphan disease drugs; FDA modernization policy issues; Reauthorization of newborn screening programs; COVID-19 telemedicine flexibility; Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients; 304B drug discount program
Client expense: $400,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA) and the orphan drug tax credit; Issues related to the use of plasma therapies in COVID-19 patients; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; The Patient Affordability, Value and Efficiency Act (not yet introduced); Discussions related to co-pay accumulators; H.R. 2279, S. 2546, Safe Step Act - provisions related to step therapy policy; H.R. 3276, S. 1785, Fair AMP Act - provisions related to AMP cap, exclusion of authorized generics from AMP; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; H.R. 2507, S. 2158, Newborn Screening Saves Lives Reauthorization of 2019 - provisions related to newborn screening; H.R. 6800, The Heroes Act - provisions related to tax issues and plasma treatments; Discussions related to Most Favored Nation/International Reference Pricing including the Executive Order; E.O. 13937, Access to Affordable Life-Saving Medications; E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients; E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen; E.O. 13947, 13948, Lowering Drug Prices by Putting America First; E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States; E.O. 13951, An America-First Healthcare Plan; E.O 13950, Combating Race and Sex Stereotyping.
Client expense: $410,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
Maternal and child health legislation, emergency preparedness and COVID-19 response efforts, tobacco control, opioids legislation and neonatal abstinence syndrome (NAS), environmental health, vaccination, newborn screening, Healthy Start, maternal mental health. Specific legislation includes: H.R. 4995, Maternal Health Quality Improvement Act of 2020, H.R. 4996, Helping Medicaid Offer Maternity Services Act of 2020, Newborn Screening Saves Lives Reauthorization Act of 2019 (HR 2507, S. 2158). Black Maternal Health Momnibus Act of 2020 (HR 6142)including the Social Determinants for Moms Act (HR 6132), the Protecting Moms who Served Act (HR 6164), the Data to Save Moms Act (HR 6165), the Moms MATTER Act (HR 6143), and Kira Johnson Act (HR 6144). Mothers and Newborns Success Act (S.4269), Maternal Health Pandemic Response Act of 2020 (H.R. 8027), Community Immunity During COVID-19 Act of 2020 (H.R. 8061), Maternal Immunization Enhancement Act (S.4690), Public Health Infrastructure Saves Lives Act (PHISLA), COVID-19 Treatment Coverage Act (S.4469)
Client expense: $130,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Postal Regulatory Commission, SENATE, Small Business Administration (SBA), Treasury, Dept of, U.S. Postal Service (USPS)
2020 · fourth_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2021 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law; HR 6238, Cameron's Law; rare kidney disease issues; HR 133, Consolidated Appropriations Act of 2021
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medicare/Medicaid
H.R. 2507 Newborn Screening Saves Lives Reauthorization Act of 2019 S. 2543 Prescription Drug Pricing Reduction Act of 2019 Proposed Rule - Establishing Minimum Standards in Medicaid State Drug Utilization Review and Supporting Value-based Purchasing for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability Requirements [CMS-2482-P]
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB)
2020 · fourth_quarter · Health Issues
Cancer Drug Parity Act (S.741 / H.R.1730) Resident Physician Shortage Reduction Act of 2019 (S. 348/H.R. 1763) Newborn Screening Saves Lives Reauthorization Act of 2019 (H.R. 2507) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Reimbursement for CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic diseases and disorders Issues impacting blood safety/shortages Issues related to convalescent plasma Healthcare Workforce Resilience Act (H.R. 6788/S. 3599) Coronavirus Provider Protection Act (H.R. 7059) Issues related to health equity/disproportionate impact of COVID-19 on minority populations Health Care at Home Act (H.R. 6644/S. 3741) Withdrawal of the United States from the World Health Organization (WHO)
Client expense: $30,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
2020 · fourth_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; Diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinsons Disease; Issues related to Telehealth; H.R. 4439/S.4010, Creating Hope Reauthorization Act; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act.
Client expense: $820,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives; drug pricing proposals; access to rare disease and gene therapy drugs, including S. 2543, The Prescription Drug Pricing Reduction Act of 2019, H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 19, the Lower Costs, More Cures Act of 2019, H.R. 5882, the GENE Therapy Payment Act, and H.R. 4439, Creating Hope Reauthorization Act; newborn screening and gene panel screening, including, H.R. 2507, the Newborn Screening Saves Lives Reauthorization Act of 2019 and S. 2158, the Newborn Screening Saves Lives Reauthorization Act of 2019; H.R. 4439, Creating Hope Reauthorization Act; and FDA approvals of drugs designed to treat rare diseases; Health care policies in P.L. 116- 123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act of CARES Act; P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act; H.R. 6800, the Heroes Act; H.R. 8406, the Heroes Act; Senate Amendment 2652 related to COVID-19 relief; P.L. 116-159, the Continuing Appropriations Act, 2021 and Other Extensions Act; and P.L.116-260, Consolidated Appropriations Act, 2021.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
H.R. 3630- No Surprises Act H.R. 2076- Early Detection to Stop Infant Abuse and Prevent Fatalities Act H.R. 2328- Community Health Investment, Modernization, and Excellence Act of 2019 H.R. 3439- PCORI Reauthorization H.R. 3030- Patient-Centered Outcomes Research Extension Act of 2019 H.R. 3666- STRONGER Patents Act 2019 S. 2082- Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019 S.2543- Prescription Drug Pricing Reduction Act of 2019 H.R. 4378- Continuing Appropriations Act, 2020, and Health Extenders Act of 2019 H.R. 2507- Newborn Screening Saves Lives Reauthorization Act of 2019 H.R. 2781- EMPOWER for Health Act of 2019 H.R. 4519- Pediatricians Accelerate Childhood Therapies Act of 2019 S. 3023- Pediatricians Accelerate Childhood Therapies Act of 2019 H.R. 3- Lower Drug Cost Now Act of 2019 H.R. 1865- Further Consolidated Appropriations Act, 2020 H.R. 6201-Families First Coronavirus Response Act H.R. 748- CARES Act H.R. 266 Paycheck Protection and Health Care Enhancement Act H.R 7233 KEEP Telehealth Options Act H.R. 7614 Fiscal 2021 Labor-HHS-Education Appropriations H.R. 6800 Health and Economic Recovery Omnibus Emergency Solutions Act S.3985 JUSTICE Act H.R. 7120 Justice in Policing Act S. 4717 Accelerating Kids Access to Care Act H.R. 5900 Accelerating Kids Access to Care Act H.R. 133 Consolidated Appropriations Act, 2021 General issues regarding mental health/ behavioral health, Medicaid, CHIP, and DSH.
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medicare/Medicaid
H.R. 3630- No Surprises Act H.R. 2076- Early Detection to Stop Infant Abuse and Prevent Fatalities Act H.R. 2328- Community Health Investment, Modernization, and Excellence Act of 2019 H.R. 3439- PCORI Reauthorization H.R. 3030- Patient-Centered Outcomes Research Extension Act of 2019 H.R. 3666- STRONGER Patents Act 2019 S. 2082- Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019 S.2543- Prescription Drug Pricing Reduction Act of 2019 H.R. 4378- Continuing Appropriations Act, 2020, and Health Extenders Act of 2019 H.R. 2507- Newborn Screening Saves Lives Reauthorization Act of 2019 H.R. 2781- EMPOWER for Health Act of 2019 H.R. 4519- Pediatricians Accelerate Childhood Therapies Act of 2019 S. 3023- Pediatricians Accelerate Childhood Therapies Act of 2019 H.R. 3- Lower Drug Cost Now Act of 2019 H.R. 1865- Further Consolidated Appropriations Act, 2020 H.R. 6201-Families First Coronavirus Response Act H.R. 748- CARES Act H.R. 266 Paycheck Protection and Health Care Enhancement Act H.R 7233 KEEP Telehealth Options Act H.R. 7614 Fiscal 2021 Labor-HHS-Education Appropriations H.R. 6800 Health and Economic Recovery Omnibus Emergency Solutions Act S.3985 JUSTICE Act H.R. 7120 Justice in Policing Act S. 4717 Accelerating Kids Access to Care Act H.R. 5900 Accelerating Kids Access to Care Act H.R. 133 Consolidated Appropriations Act, 2021 General issues regarding mental health/ behavioral health, Medicaid, CHIP, and DSH.
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
Legislation and policies relating to: Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Reauthorization of funding for the Childrens Health Insurance Program Reauthorization of the Child Nutrition Act Section 2706 of the ACA regarding provider non-discrimination Policies related to health insurance market stabilization Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Health information technology and electronic health records Mental health services and violence prevention Human and child trafficking Palliative Care and Hospice Education and Training Act (H.R. 647/S. 2080) Title VIII Nursing Workforce Reauthorization Act of 2019 (H.R. 728/S. 1399) Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748/S.3548) Emergency Medical Services for Children Program Reauthorization Act of 2019 (H.R. 776/S. 1173) End Surprise Billing Act of 2019 (H.R. 861) Fairness for Breastfeeding Mothers Act (H.R. 866/S. 528) Mental Health Access Improvement Act of 2019 (H.R. 945) Workplace Violence Prevention for Health Care and Social Service Workers Act (H.R. 1309) Patient Protection and Affordable Care Enhancement Act (H.R. 1425) Healthy Families Act (H.R. 1784/S. 840) Mothers and Offspring Mortality and Morbidity Awareness (MOMMAs) Act (H.R. 1897) School-Based Health Centers Reauthorization Act of 2019 (H.R. 2075/S. 1013) Scarlett's Sunshine on Sudden Unexpected Death Act (H.R. 2271/S. 1130) Community Health Investment, Modernization, and Excellence Act of 2019 (H.R. 2328) Newborn Screening Saves Lives Reauthorization Act of 2019 (H.R. 2507) Pregnant Workers Fairness Act (H.R. 2694) Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act of 2019 (H.R. 2781) Vaccine Awareness Campaign to Champion Immunization Nationally and Enhance Safety (VACCINES) Act of 2019 (H.R. 2862) Physical Activities Recommendations for Americans Act of 2019 (H.R. 2891) Safe Cribs Act of 2019 (H.R. 3170) Safe Sleep for Babies Act of 2019 (H.R. 3172) Pathways to Health Careers Act (H.R. 3398) Chronic Care Management Improvement Act (H.R. 3436) No Surprises Act (H.R. 3630) Midwives for Maximizing Optimal Maternity Services (Midwives for MOMS) Act of 2019 (H.R. 3849) Social Determinants Accelerator Act of 2019 (H.R. 4004/S. 2986) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 (H.R. 3328/H.R. 4100/S. 1712) Effective Suicide Screening and Assessment in the Emergency Department Act of 2019 (H.R. 4861/S. 3006) United States Public Health Service Modernization Act of 2019 (H.R. 4870/S. 2629) Medication Access and Training Expansion (MATE) Act of 2019 (H.R. 4974) Maternal Health Quality Improvement Act of 2019 (H.R. 4995) Helping Medicaid Offer Maternity Services (MOMS) Act of 2019 (H.R. 4996) Protecting Seniors Through Immunization Act of 2019 (H.R. 5076/S. 1872) Pursuing Equity in Mental Health Act of 2019 (H.R. 5469) Primary and Behavioral Health Care Access Act (H.R. 5575) Ban Surprise Billing Act (H.R. 5800) Consumer Protections Against Surprise Medical Bills Act of 2020 (H.R. 5826) Black Maternal Health Momnibus Act of 2020 (H.R. 6142/S. 3424) Families First Coronavirus Response Act (H.R. 6201) Take Responsibility for Workers and Families Act (H.R. 6379) Health Care at Home Act (H.R. 6644) COVID-19 Mental Health Research Act (H.R. 6645) HEROES Act (H.R. 6800) Child Care Is Essential Act (H.R. 7027) Ensuring Children and Child Care Workers Are Safe Act of 2020 (H.R. 7079) Child Care for Economic Recovery Act (H.R. 7327) Protect Telehealth Access Act (H.R. 7391) Protecting Access to Post-COVID-19 Telehealth Act of 2020 (H.R. 7663) Community and Public Health Programs Extension Act (S. 192) National Nurse Act of 2019 (S. 696/H.R. 1597) Excellence in Mental Health and Addiction Treatment Expansion Act (S. 824/H.R. 1767) Nursing Where It's Needed Act (S. 1045) Promoting Physical Activity for Americans Act (S. 1608) Lower Health Care Costs Act (S. 1895) National Suicide Hotline Designation Act (S. 2661) Child Care Protection Improvement Act of 2019 (S. 2683) CONNECT for Health Act of 2019(S. 2741/H.R. 4932) CAPTA Reauthorization Act of 2019 (S. 2971) Suicide Prevention Act (S. 3198/H.R. 5619) Eliminating Abusive and Rampant Neglect of Interactive Technologies (EARN IT) Act of 2020 (S. 3398) Tele-Mental Health Improvement Act (S. 3792) Coronavirus Mental Health and Addiction Assistance Act of 2020 (S. 3825/H.R. 6999) Future Advancement of Academic Nursing (FAAN) Act (S. 4396/H.R. 7945) Safe Authorization for Vaccines during Emergencies (SAVE) Act (S. 4427)
Client expense: Not reported · Firm income: $24,000
Government targets: Bureau of Alcohol Tobacco Firearms & Explosives, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, Veterans Affairs, Dept of (VA), Vice President of the U.S., White House Office
2020 · third_quarter · Health Issues
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for passage of H.R. 4393, the Advancing Access to Precision Medicine Act, provide for a State option under the State Medicaid plan to provide DNA sequencing clinical services for certain children. Advocated for funding for the FDA Orphan Products Grants Program. Advocated for passage of H.R. 3235, the Access to Genetic Counselor Services Act of 2019, to provide for expanded coverage of services provided by genetic counselors. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 2507 / S. 2158, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for robust funding of the national newborn screening program. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019. Advocated for maintaining strong incentives for rare disease drug development included within the Orphan Drug Act (PL 97-414) Advocated on the Promising Pathway Act (S.3872) and the ACT for ALS Act (H.R.7071). Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency. H.R. 6800, HEROES Act and related COVID-19 packages, support various provisions relevant to people with NMDs including increased federal support for state Medicaid programs; Medicaid maintenance of effort provisions; nationwide reopening of Marketplace special enrollment period; expansion of paid sick leave and paid family and medical leave; making permanent flexibilities to allow Medicare beneficiaries to continue accessing healthcare through telehealth; more resources to enhance testing and contact tracing in underserved communities; opposing waivers from IDEA and the Rehab Act; and better data collection on the impact of COVID-19 on people with disabilities. Continuing to support passage of legislation and proposals to protect patients from surprise medical billing and hold patients harmless.
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2020 · third_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA) and the orphan drug tax credit; Issues related to the use of plasma therapies in COVID-19 patients; Communications with DFC regarding Project Warp Speed - provisions related to use of plasma to treat COVID-19; H.R. 1425, The Patient Protection and Affordable Care Enhancement Act Discussions to clarify or reform the 340B program; S.4160 - A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes - provisions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; H.R. 1035; Prescription Drug Price Transparency Act - provisions related to drug pricing transparency and pharmacy benefit managers; S. 378, H.R. 1093, The Stop Price Gouging Act - provisions related to prescription drug pricing; Discussions related to co-pay accumulators; S. 657, Drug Price Transparency Act - provisions related to prescription drug pricing transparency and commercial market rebates; H.R. 2279, S. 2546, Safe Step Act - provisions related to step therapy policy; H.R. 3276, S. 1785, Fair AMP Act - provisions related to AMP cap, exclusion of authorized generics from AMP; H.R. 3, Lower Drug Costs Now Act of 2019 - provisions related to the establishment of programs and requirements relating to the prices of prescription drugs; H.R. 19, Lower Costs, More Cures Act of 2019 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; VA MISSION Act of 2018 (P.L. 115 - 182) - provisions related to healthcare coverage after dischange from active duty; H.R. 5201, Telemental Health Expansion Act of 2019 - provisions related to mental telehealth coverage; Issues related to global pharmaceutical supply chain operations and manufacturing locations; H.R. 2507, S. 2158, Newborn Screening Saves Lives Reauthorization of 2019 - provisions related to newborn screening; H.R. 6800, The Heroes Act - provisions related to tax issues and plasma treatments; Discussions related to Most Favored Nation/International Reference Pricing including the Executive Order; E.O. 13937, Access to Affordable Life-Saving Medications; E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients; E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen; E.O. 13947, 13948, Lowering Drug Prices by Putting America First; E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States; E.O. 13951, An America-First Healthcare Plan; E.O 13950, Combating Race and Sex Stereotyping.
Client expense: $1,160,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2020 · third_quarter · Medical/Disease Research/Clinical Labs
H.R. 2507: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions H.R. 4932: Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019; all provisions H.R. 6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; Provisions related to paid family and medical leave, personal protective equipment, and access to medicine, nutrition assistance programs, and antimicrobial research H.R. 7269: Promising Pathway Act; all provisions H.R. 8337: Continuing Appropriations Act, 2021 and Other Extensions Act; Provisions related to funding for the National Institutes of Health (NIH), Food and Drug Administration (FDA), and related agencies S. 2158: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions S. 2741: Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019; all provisions S. 3872: Promising Pathway Act; all provisions Discussions surrounding additional coronavirus relief measures; provisions related to paid family and medical leave, personal protective equipment, and access to medicine, nutrition assistance programs, and antimicrobial research (Draft) 21st Century Cures 2.0; all provisions of the draft (Draft) Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020; all provisions of the draft (Draft) Labor, Health and Human Services (LHHS) Appropriations for Fiscal Year 2021; provisions related to funding for Health and Human Services and related agencies (Draft) Draft Agriculture Appropriations for Fiscal Year 2021; provisions related to funding for the Food and Drug Administration and related agencies
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
H.R. 2507: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions H.R. 4100: Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019; all provisions H.R. 4386: Stop the Wait Act; all provisions H.R. 4932: Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019; all provisions H.R. 6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; provisions related to paid family and medical leave, personal protective equipment, and access to medicine, nutrition assistance programs, and antimicrobial research H.R. 7269: Promising Pathway Act; all provisions S. 1712: Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019; all provisions S. 2158: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions S. 2496: Stop the Wait Act; all provisions S. 2741: Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019; all provisions S. 3872: Promising Pathway Act; all provisions S. 4421: Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act; all provisions S. 4557: COVID Enrollment Response (COVER) Act; all provisions Discussions surrounding additional coronavirus relief measures; provisions related to paid family and medical leave, personal protective equipment, and access to medicine, nutrition assistance programs, and antimicrobial research (Draft) 21st Century Cures 2.0; all provisions of the draft (Draft) Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020; all provisions of the draft
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2021 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law; HR 6238, Cameron's Law; rare kidney disease issues
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT; ALL PROVISIONS OF THE BILL H.R. 7567: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEARTS) ACT OF 2020; ALL PROVISIONS OF THE BILL H.R. 7647: TO PROVIDE FOR A COVID-19-RELATED DELAY REGARDING ANNUAL LIMITATION ON COST-SHARING FOR GROUP HEALTH PLANS AND INDIVIDUAL AND SMALL GROUP HEALTH INSURANCE COVERAGE; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FOOD & DRUG ADMINISTRATION'S COMPLETE RESPONSE LETTER; BREAKTHROUGH THERAPY PROGRAM; HEALTH INNOVATION; NEWBORN SCREENING; VALUE BASED ARRANGEMENTS
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Cancer Drug Parity Act (S.741 / H.R.1730) Resident Physician Shortage Reduction Act of 2019 (S. 348/H.R. 1763) Newborn Screening Saves Lives Reauthorization Act of 2019 (H.R. 2507) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Reimbursement for CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic diseases and disorders Issues impacting blood safety/shortages Issues related to convalescent plasma Healthcare Workforce Resilience Act (H.R. 6788/S. 3599) Coronavirus Provider Protection Act (H.R. 7059) Issues related to health equity/disproportionate impact of COVID-19 on minority populations Health Care at Home Act (H.R. 6644/S. 3741) Withdrawal of the United States from the World Health Organization (WHO)
Client expense: $30,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
2020 · third_quarter · Health Issues
Maternal and child health legislation,focusing on National Children's Study (ECHO), Zika preparedness, tobacco control, opioids legislation and neonatal abstinence syndrome (NAS), antibiotic resistance, environmental health, vaccination, newborn screening, Healthy Start, maternal mental health. Specific legislation includes: MOMMAs Act (H.R. 1897/S. 916, MOMs Act (S. 116),MOMMIES Act (H.R. 2602, S. 1343), Quality Care for Moms and Babies Act (H.R. 1551/S. 1960), Maternal CARE Act (H.R. 6698/S. 1600), The Healthy Maternity and Obstetric Medicine Act (Healthy MOM Act) (H.R. 2778/S. 1481), Rural Maternal and Obstetric Modernization of Services (MOMS) Act (S. 2373), the Maternal Outcomes Matter Act of 2019 (S. 2586), Healthy Maternity and Obstetric Medicine Act (H.R. 2778, S. 1481), H.R. 4995, Maternal Health Quality Improvement Act of 2019, H.R. 4996, Helping Medicaid Offer Maternity Services Act of 2019, Reversing the Youth Tobacco Epidemic Act (H.R. 2339), Public Health Funding Restoration Act (H.R. 3447, S. 1944), and the Comprehensive Addiction Resources Emergency CARE Act (H.R. 2569, S. 1365), Newborn Screening Saves Lives Reauthorization Act of 2019 (HR 2507/S. 2158), Traveling Parents Screening Consistency Act (HR 3246), the Tobacco Tax Equity Act (S. 2517), EQUIP Act of 2020 (HR 6178), and the Protecting American Lungs Act of 2019 (HR 4742). Black Maternal Health Momnibus Act of 2020 (HR 6142)including the Social Determinants for Moms Act (HR 6132), the Protecting Moms who Served Act (HR 6164), the Data to Save Moms Act (HR 6165), the Moms MATTER Act (HR 6143), and Kira Johnson Act (HR 6144). Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123), Families First Coronavirus Response Act (P.L. 116-127), Coronavirus Aid, Relief, and Economic Security (CARES) Act (HR 748) (P.L. 116-136), and HEROES Act (H.R. 6800). Mothers and Newborns Success Act (S.4269), Maternal Health Pandemic Response Act of 2020 (H.R. 8027), Community Immunity During COVID-19 Act of 2020 (H.R. 8061), Maternal Immunization Enhancement Act (S.4690), Public Health Infrastructure Saves Lives Act (PHISLA), COVID-19 Treatment Coverage Act (S.4469)
Client expense: $50,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Postal Regulatory Commission, SENATE, Treasury, Dept of, U.S. Postal Service (USPS)
2020 · third_quarter · Health Issues
S. 2158 / H.R. 2507--Newborn Screening Saves Lives Reauthorization Act Executive Order 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States General issues related to orphan disease drugs; FDA modernization policy issues; Reauthorization of newborn screening programs; general issues related to drug cost and pricing policies; general discussions on the Patient Centered Outcomes Research Institute; COVID-19 telemedicine flexibility; Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
H.R. 2507 Newborn Screening Saves Lives Reauthorization Act of 2019 S. 2543 Prescription Drug Pricing Reduction Act of 2019 Proposed Rule - Establishing Minimum Standards in Medicaid State Drug Utilization Review and Supporting Value-based Purchasing for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability Requirements [CMS-2482-P]
Client expense: $200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB)
2020 · third_quarter · Health Issues
Regulatory and legislative health care issues impacting pricing and access; Diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinsons Disease; Issues related to Telehealth; H.R. 4439/S.4010, Creating Hope Reauthorization Act; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act.
Client expense: $480,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
H.R. 3630- No Surprises Act H.R. 2076- Early Detection to Stop Infant Abuse and Prevent Fatalities Act H.R. 2328- Community Health Investment, Modernization, and Excellence Act of 2019 H.R. 3439- PCORI Reauthorization H.R. 3030- Patient-Centered Outcomes Research Extension Act of 2019 H.R. 3666- STRONGER Patents Act 2019 S. 2082- Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019 S.2543- Prescription Drug Pricing Reduction Act of 2019 H.R. 4378- Continuing Appropriations Act, 2020, and Health Extenders Act of 2019 H.R. 2507- Newborn Screening Saves Lives Reauthorization Act of 2019 H.R. 2781- EMPOWER for Health Act of 2019 H.R. 4519- Pediatricians Accelerate Childhood Therapies Act of 2019 S. 3023- Pediatricians Accelerate Childhood Therapies Act of 2019 H.R. 3- Lower Drug Cost Now Act of 2019 H.R. 1865- Further Consolidated Appropriations Act, 2020 H.R. 6201-Families First Coronavirus Response Act H.R. 748- CARES Act H.R. 266 Paycheck Protection and Health Care Enhancement Act H.R 7233 KEEP Telehealth Options Act H.R. 7614 Fiscal 2021 Labor-HHS-Education Appropriations H.R. 6800 Health and Economic Recovery Omnibus Emergency Solutions Act S.3985 JUSTICE Act H.R. 7120 Justice in Policing Act S. 4717 Accelerating Kids Access to Care Act H.R. 5900 Accelerating Kids Access to Care Act General issues regarding mental health/ behavioral health, Medicaid, CHIP, and DSH.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
H.R. 3630- No Surprises Act H.R. 2076- Early Detection to Stop Infant Abuse and Prevent Fatalities Act H.R. 2328- Community Health Investment, Modernization, and Excellence Act of 2019 H.R. 3439- PCORI Reauthorization H.R. 3030- Patient-Centered Outcomes Research Extension Act of 2019 H.R. 3666- STRONGER Patents Act 2019 S. 2082- Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019 S.2543- Prescription Drug Pricing Reduction Act of 2019 H.R. 4378- Continuing Appropriations Act, 2020, and Health Extenders Act of 2019 H.R. 2507- Newborn Screening Saves Lives Reauthorization Act of 2019 H.R. 2781- EMPOWER for Health Act of 2019 H.R. 4519- Pediatricians Accelerate Childhood Therapies Act of 2019 S. 3023- Pediatricians Accelerate Childhood Therapies Act of 2019 H.R. 3- Lower Drug Cost Now Act of 2019 H.R. 1865- Further Consolidated Appropriations Act, 2020 H.R. 6201-Families First Coronavirus Response Act H.R. 748- CARES Act H.R. 266 Paycheck Protection and Health Care Enhancement Act H.R 7233 KEEP Telehealth Options Act H.R. 7614 Fiscal 2021 Labor-HHS-Education Appropriations H.R. 6800 Health and Economic Recovery Omnibus Emergency Solutions Act S.3985 JUSTICE Act H.R. 7120 Justice in Policing Act S. 4717 Accelerating Kids Access to Care Act H.R. 5900 Accelerating Kids Access to Care Act General issues regarding mental health/ behavioral health, Medicaid, CHIP, and DSH.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives; drug pricing proposals; access to rare disease and gene therapy drugs, including S. 2543, The Prescription Drug Pricing Reduction Act of 2019, H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 19, the Lower Costs, More Cures Act of 2019, H.R. 5882, the GENE Therapy Payment Act, and H.R. 4439, Creating Hope Reauthorization Act; newborn screening and gene panel screening, including, H.R. 2507, the Newborn Screening Saves Lives Reauthorization Act of 2019 and S. 2158, the Newborn Screening Saves Lives Reauthorization Act of 2019; and FDA approvals of drugs designed to treat rare diseases. Health care policies in P.L. 116- 123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act of CARES Act; P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act; H.R. 6800, the Heroes Act; H.R. 8406, the Heroes Act; Senate Amendment 2652 related to COVID-19 relief; and H.R. 8337, the Continuing Appropriations Act, 2021 and Other Extensions Act.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Medical/Disease Research/Clinical Labs
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
Legislation and policies relating to: Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Reauthorization of funding for the Childrens Health Insurance Program Reauthorization of the Child Nutrition Act Section 2706 of the ACA regarding provider non-discrimination Policies related to health insurance market stabilization Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Health information technology and electronic health records Mental health services and violence prevention Human and child trafficking Palliative Care and Hospice Education and Training Act (H.R. 647/S. 2080) Title VIII Nursing Workforce Reauthorization Act of 2019 (H.R. 728/S. 1399) Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748/S.3548) Emergency Medical Services for Children Program Reauthorization Act of 2019 (H.R. 776/S. 1173) End Surprise Billing Act of 2019 (H.R. 861) Fairness for Breastfeeding Mothers Act (H.R. 866/S. 528) Mental Health Access Improvement Act of 2019 (H.R. 945) Workplace Violence Prevention for Health Care and Social Service Workers Act (H.R. 1309) Patient Protection and Affordable Care Enhancement Act (H.R. 1425) Healthy Families Act (H.R. 1784/S. 840) Mothers and Offspring Mortality and Morbidity Awareness (MOMMAs) Act (H.R. 1897) Community Health Investment, Modernization, and Excellence Act of 2019 (H.R. 2328) Newborn Screening Saves Lives Reauthorization Act of 2019 (H.R. 2507) Pregnant Workers Fairness Act (H.R. 2694) Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act of 2019 (H.R. 2781) Vaccine Awareness Campaign to Champion Immunization Nationally and Enhance Safety (VACCINES) Act of 2019 (H.R. 2862) Physical Activities Recommendations for Americans Act of 2019 (H.R. 2891) Safe Cribs Act of 2019 (H.R. 3170) Safe Sleep for Babies Act of 2019 (H.R. 3172) Pathways to Health Careers Act (H.R. 3398) Chronic Care Management Improvement Act (H.R. 3436) No Surprises Act (H.R. 3630) Social Determinants Accelerator Act of 2019 (H.R. 4004/S. 2986) United States Public Health Service Modernization Act of 2019 (H.R. 4870/S. 2629) Maternal Health Quality Improvement Act of 2019 (H.R. 4995) Helping Medicaid Offer Maternity Services (MOMS) Act of 2019 (H.R. 4996) Protecting Seniors Through Immunization Act of 2019 (H.R. 5076/S. 1872) Pursuing Equity in Mental Health Act of 2019 (H.R. 5469) Primary and Behavioral Health Care Access Act (H.R. 5575) Ban Surprise Billing Act (H.R. 5800) Consumer Protections Against Surprise Medical Bills Act of 2020 (H.R. 5826) Black Maternal Health Momnibus Act of 2020 (H.R. 6142/S. 3424) Families First Coronavirus Response Act (H.R. 6201) Take Responsibility for Workers and Families Act (H.R. 6379) Health Care at Home Act (H.R. 6644) COVID-19 Mental Health Research Act (H.R. 6645) HEROES Act (H.R. 6800) Protect Telehealth Access Act (H.R. 7391) Community and Public Health Programs Extension Act (S. 192) National Nurse Act of 2019 (S. 696/H.R. 1597) Excellence in Mental Health and Addiction Treatment Expansion Act (S. 824/H.R. 1767) Nursing Where It's Needed Act (S. 1045) Promoting Physical Activity for Americans Act (S. 1608) Lower Health Care Costs Act (S. 1895) Child Care Improvement Act of 2019 (S. 2683) CONNECT for Health Act of 2019(S. 2741/H.R. 4932) CAPTA Reauthorization Act of 2019 (S. 2971) Suicide Prevention Act (S. 3198/H.R. 5619) Eliminating Abusive and Rampant Neglect of Interactive Technologies (EARN IT) Act of 2020 (S. 3398) Tele-Mental Health Improvement Act (S. 3792) Coronavirus Mental Health and Addiction Assistance Act of 2020 (S. 3825/H.R. 6999)
Client expense: Not reported · Firm income: $24,000
Government targets: Bureau of Alcohol Tobacco Firearms & Explosives, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, Veterans Affairs, Dept of (VA), Vice President of the U.S., White House Office
2020 · second_quarter · Health Issues
Maternal and child health legislation,focusing on National Children's Study (ECHO), Zika preparedness, tobacco control, opioids legislation and neonatal abstinence syndrome (NAS), antibiotic resistance, environmental health, vaccination, newborn screening, Healthy Start, maternal mental health. Specific legislation includes: MOMMAs Act (H.R. 1897/S. 916, MOMs Act (S. 116),MOMMIES Act (H.R. 2602, S. 1343), Quality Care for Moms and Babies Act (H.R. 1551/S. 1960), Maternal CARE Act (H.R. 6698/S. 1600), The Healthy Maternity and Obstetric Medicine Act (Healthy MOM Act) (H.R. 2778/S. 1481), Rural Maternal and Obstetric Modernization of Services (MOMS) Act (S. 2373), the Maternal Outcomes Matter Act of 2019 (S. 2586), Healthy Maternity and Obstetric Medicine Act (H.R. 2778, S. 1481), H.R. 4995, Maternal Health Quality Improvement Act of 2019, H.R. 4996, Helping Medicaid Offer Maternity Services Act of 2019, Reversing the Youth Tobacco Epidemic Act (H.R. 2339), Public Health Funding Restoration Act (H.R. 3447, S. 1944), and the Comprehensive Addiction Resources Emergency CARE Act (H.R. 2569, S. 1365), Newborn Screening Saves Lives Reauthorization Act of 2019 (HR 2507/S. 2158), Traveling Parents Screening Consistency Act (HR 3246), the Tobacco Tax Equity Act (S. 2517), EQUIP Act of 2020 (HR 6178), and the Protecting American Lungs Act of 2019 (HR 4742). Black Maternal Health Momnibus Act of 2020 (HR 6142)including the Social Determinants for Moms Act (HR 6132), the Protecting Moms who Served Act (HR 6164), the Data to Save Moms Act (HR 6165), the Moms MATTER Act (HR 6143), and Kira Johnson Act (HR 6144). Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123), Families First Coronavirus Response Act (P.L. 116-127), Coronavirus Aid, Relief, and Economic Security (CARES) Act (HR 748) (P.L. 116-136), and HEROES Act (H.R. 6800).
Client expense: $50,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Postal Regulatory Commission, SENATE, Treasury, Dept of, U.S. Postal Service (USPS)
2020 · second_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care, for rare kidney disease.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Health Issues
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE